Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...
The "Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers a comprehensive analysis of current and future ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2 ARROW ...
Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it ...
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers ...
Humanetics Corporation (Humanetics) announced today the launch of a new investigator-initiated clinical trial (IIT) of BIO 300 Oral Suspension (BIO 300), led by Dr. Narek Shaverdian, Director of ...
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study ...
Starting treatment of study participants in the RASolute 303 trial represents an important milestone for our daraxonrasib program and for patients with metastatic pancreatic cancer, a disease with ...
MAIA Biotechnology, Inc. announced that eight patients with non-small cell lung cancer in an ongoing phase 2 THIO-101 ...
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, ...
U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results